首页 | 本学科首页   官方微博 | 高级检索  
检索        

肺癌获得性多药耐药机制的研究进展
引用本文:梁丽峰,戢福云,马李杰,赵诣林,陈向军,金发光.肺癌获得性多药耐药机制的研究进展[J].国际呼吸杂志,2014,34(14):1111-1115.
作者姓名:梁丽峰  戢福云  马李杰  赵诣林  陈向军  金发光
作者单位:梁丽峰 (第四军医大学唐都医院呼吸与危重症医学科, 西安,710038); 戢福云 (第三军医大学新桥医院全军呼吸内科研究所, 重庆,400037); 马李杰 (第四军医大学唐都医院呼吸与危重症医学科, 西安,710038); 赵诣林 (第四军医大学唐都医院呼吸与危重症医学科, 西安,710038); 陈向军 (第四军医大学唐都医院呼吸与危重症医学科, 西安,710038); 金发光 (第四军医大学唐都医院呼吸与危重症医学科, 西安,710038);
基金项目:国家自然科学基金(项目编号:81071933)
摘    要:肺癌对人类健康的危害日益严重,从20世纪中叶开始,其发病率和病死率在全球范围内迅速增长,而患者的5年生存率却徘徊在10%左右。化疗是肺癌综合治疗的重要手段之一,然而近年来,多药耐药的不断出现严重限制了肺癌化疗效果的提高。多药耐药机制的研究有望为逆转耐药提供全新的思路。

关 键 词:肺癌  多药耐药  获得性

Study progress on formation mechanism of multidrug resistance of lung cancer
Institution:Liang Lifeng ,Ji Fuyun, Ma Lijie , Zhao Yilin , Chert Xiangjun , Jin Faguang. (Department of Respiratory and Critical Care Medicine, Tangdu Hospital ,the Fourth Military Medical University ,Xilan 710038 ,China)
Abstract:Lung cancer is becoming increasingly serious harm to human health. From the mid-20th century,its morbidity and mortality are growing fast around the world, but 5-year survival rate of the patients is hovering at 10 % approximately. Chemotherapy is one of the important means of comprehensive treatment of lung cancer, however, in recent years, the continual emergence of multi-drug resistance severely limits the improvement of lung cancer chemotherapy. And, the research of the multi-drug resistance mechanism is expected to provide a new train of thought to reverse drug resistance.
Keywords:Lung cancer  Multidrug resistances Acquired
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号